Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy

European Journal of Cancer

Volumn 51, Issue 1, 2015, Pages 18-26

  Ruff, Paul ^a   Ferry, David R ^b   Lakom, Radek ^c   Prausová, Jana ^d   Van Hazel, Guy A ^e   Hoff, Paulo M ^f   Cunningham, David ^g   Arnold, Dirk ^h   Schmoll, Hans J ⁱ   Moiseyenko, Vladimir M ^j   McKendrick, Joseph J ^k   Ten Tije, Albert J ^l   Vishwanath, Raghu L ^m   Bhargava, Pankaj ⁿ   Chevalier, Soazig ^o   Macarulla, Teresa ^p   Van Cutsem, Eric ^q  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b RUSSELLS HALL HOSPITAL   (United Kingdom)

^c MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^d UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f HOSPITAL SÍRIO LIBANÊS   (Brazil)

^g ROYAL MARSDEN HOSPITAL   (United Kingdom)

^h TUMOR BIOLOGY CENTER   (Germany)

ⁱ MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^j N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^k MONASH UNIVERSITY   (Australia)

^l AMPHIA HOSPITAL   (Netherlands)

^m Global Medical   (United States)

ⁿ Immunology and Inflammation Development Franchise   (United States)

^o SANOFI   (France)

^p HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^q UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

Aflibercept; Colorectal cancer; Efficacy; PlGF; Safety; VEGF A; VEGF B

Indexed keywords

AFLIBERCEPT; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; HYBRID PROTEIN; PHARMACOLOGICAL BIOMARKER; PLATINUM COMPLEX; VASCULOTROPIN RECEPTOR;

ADD ON THERAPY; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FOLLOW UP; HAZARD RATIO; HEART DISEASE; HUMAN; HYPERTENSION; INFECTION; MAJOR CLINICAL STUDY; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NEPHROTIC SYNDROME; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; WOUND HEALING; ANALOGS AND DERIVATIVES; COLORECTAL TUMOR; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; MALE; METASTASIS; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS;

EID: 84925252758     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.10.019     Document Type: Article

References (27)

1. R.M. Goldberg, D.J. Sargent, and R.F. Morton A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 1 2004 23 30
2. L.B. Saltz, J.V. Cox, and C. Blanke Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 13 2000 905 914
3. C. Tournigand, T. Andre, and E. Achille FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 2 2004 229 237
4. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2004 2335 2342
5. R.M. Goldberg, M.L. Rothenberg, and E. Van Cutsem The continuum of care: a paradigm for the management of metastatic colorectal cancer Oncologist 12 1 2007 38 50
6. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines®) colon cancer. Version 3.2013. Available at < http://www.nccn.org/professionals/physician-gls/pdf/colon.pdf > [accessed 22.10.12].
7. H.J. Schmoll, E. Van Cutsem, and A. Stein ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making Ann Oncol 23 10 2012 2479 2516
8. Y. Inoue, Y. Toiyama, K. Tanaka, C. Miki, and M. Kusunoki A comprehensive comparative study on the characteristics of colorectal cancer chemotherapy Jpn J Clin Oncol 39 6 2009 367 375
9. E. Van Cutsem, J. Tabernero, and R. Lakomy Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen J Clin Oncol 30 28 2012 3499 3506
10. B.J. Giantonio, P.J. Catalano, and N.J. Meropol Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 12 2007 1539 1544
11. J. Bennouna, J. Sastre, and D. Arnold Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial Lancet Oncol 14 1 2013 29 37
12. A.F. Sobrero, J. Maurel, and L. Fehrenbacher EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer J Clin Oncol 26 14 2008 2311 2319
13. M. Peeters, T.J. Price, and A. Cervantes Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer J Clin Oncol 28 31 2010 4706 4713
14. J.R. Hecht, A.L. Cohn, and S.R. Dakhil SPIRITT (study 20060141): a randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) J Clin Oncol 31 4 (Suppl) 2013 [Abstract 454]
15. N. Papadopoulos, J. Martin, and Q. Ruan Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab Angiogenesis 15 2 2012 171 185
16. A. Yousif, and A.A.A. Yasar The role of the therapeutic promise of targeted angiogenesis inhibitor in management of metastatic colorectal cancer Cancer Ther 9 2013 55 64
17. B. Sennino, and D.M. McDonald Controlling escape from angiogenesis inhibitors Nat Rev Cancer 12 10 2012 699 709
18. A. Sobrero, S. Ackland, and S. Clarke Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer Oncology 77 2 2009 113 119
19. C.S. Fuchs, J. Marshall, and E. Mitchell Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study J Clin Oncol 25 30 2007 4779 4786
20. Y. Horita, Y. Yamada, and K. Kato Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial Int J Clin Oncol 17 6 2012 604 609
21. S. Stintzing, L. Fischer von Weikersthal, and T. Decker FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306 Ann Oncol 23 7 2012 1693 1699
22. M. Suenaga, S. Matsusaka, and M. Ueno Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients Surg Today 41 8 2011 1067 1074
23. S. Niraula, B. Seruga, and A. Ocana The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs J Clin Oncol 30 24 2012 3012 3019
24. J. Tabernero, E. Van Cutsem, and R. Lakomy Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial Eur J Cancer 50 2 2014 320 331
25. Assessment report for Avastin Procedure No. EMEA/H/C/00582/II/014.
26. Assessment Report for Erbitux Procedure No. EMEA/H/C/000558/II/0020.
27. D. Ferry, T.W. Kim, and T.K. Guren On-treatment progression-free survival analysis of ziv-aflibercept/FOLFIRI treatment within 28 days of end of treatment in metastatic colorectal cancer: updated efficacy results from the VELOUR study J Clin Oncol 31 4 Suppl 2013 [abstr 3573]